EXASEXACT SCIENCES CORP

Nasdaq exactsciences.com


$ 59.44 $ -1.93 (-3.14 %)    

Wednesday, 08-May-2024 15:59:55 EDT
QQQ $ 439.55 $ -0.26 (-0.06 %)
DIA $ 390.50 $ 1.74 (0.45 %)
SPY $ 517.10 $ 0.05 (0.01 %)
TLT $ 90.18 $ -0.55 (-0.61 %)
GLD $ 213.58 $ -0.63 (-0.29 %)
$ 59.48
$ 60.70
$ 0.00 x 0
$ 0.00 x 0
$ 59.04 - $ 62.11
$ 56.05 - $ 100.77
3,378,695
na
10.98B
$ 1.19
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 02-21-2024 12-31-2023 10-K
3 11-01-2023 09-30-2023 10-Q
4 08-01-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 02-21-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-02-2022 06-30-2022 10-Q
9 04-26-2022 03-31-2022 10-Q
10 02-22-2022 12-31-2021 10-K
11 11-02-2021 09-30-2021 10-Q
12 07-28-2021 06-30-2021 10-Q
13 05-04-2021 03-31-2021 10-Q
14 02-16-2021 12-31-2020 10-K
15 10-27-2020 09-30-2020 10-Q
16 07-31-2020 06-30-2020 10-Q
17 05-06-2020 03-31-2020 10-Q
18 02-21-2020 12-31-2019 10-K
19 10-30-2019 09-30-2019 10-Q
20 07-30-2019 06-30-2019 10-Q
21 04-30-2019 03-31-2019 10-Q
22 02-21-2019 12-31-2018 10-K
23 10-30-2018 09-30-2018 10-Q
24 08-01-2018 06-30-2018 10-Q
25 04-26-2018 03-31-2018 10-Q
26 02-22-2018 12-31-2017 10-K
27 10-30-2017 09-30-2017 10-Q
28 07-25-2017 06-30-2017 10-Q
29 04-27-2017 03-31-2017 10-Q
30 02-21-2017 12-31-2016 10-K
31 10-26-2016 09-30-2016 10-Q
32 07-26-2016 06-30-2016 10-Q
33 05-03-2016 03-31-2016 10-Q
34 02-24-2016 12-31-2015 10-K
35 10-30-2015 09-30-2015 10-Q
36 07-31-2015 06-30-2015 10-Q
37 05-04-2015 03-31-2015 10-Q
38 02-27-2015 12-31-2014 10-K
39 10-31-2014 09-30-2014 10-Q
40 08-01-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 exact-sciences-stock-plunges-on-q1-earnings-what-you-need-to-know

Exact Sciences said first-quarter revenue increased 6% year-over-year to $638 million, which beat the consensus estimate of $62...

 exact-sciences-q1-2024-gaap-eps-060-misses-048-estimate-sales-638000m-beat-627365m-estimate

Exact Sciences (NASDAQ:EXAS) reported quarterly losses of $(0.60) per share which missed the analyst consensus estimate of $(0....

 stocks-falter-as-fed-signals-need-for-higher-for-longer-rates-uber-crashes-energy-sector-loses-ground-whats-driving-wednesdays-market

Wednesday witnessed a tempering of the bullish sentiment that had buoyed Wall Street in recent sessions, with major indices sho...

 wall-street-poised-for-muted-open-on-mixed-earnings-with-more-fed-speeches-in-store-analyst-sees-sp-500-crossing-late-march-high

U.S. stocks are on track for a mixed start on Wednesday as the market digests mixed earnings reports and looks ahead to more sp...

 will-earnings-cheer-continue-this-week-all-eyes-on-disney-palantir-robinhood-while-reddit-gears-up-for-debut-quarterly-report

According to FactSet, a financial data analytics firm, 80% of S&P 500 companies have reported earnings so far.

 exact-sciences-appoints-aaron-bloomer-as-cfo-effective-may-15-2024

To help facilitate a smooth transition, Bloomer joins the company as executive vice president, finance, effective immediately, ...

 exact-sciences-announces-debt-exchange-transaction-and-private-placement-of-convertible-senior-notes

On April 10, 2024 it entered into privately negotiated exchange and purchase agreements (the "Agreements") with certain...

 exact-sciences-to-present-late-breaking-data-from-ascend-2-study-validating-its-investigational-multi-cancer-early-detection-test-at-aacr-annual-meeting-2024

First analysis from ASCEND-2 confirms high detection rates and specificity achieved with multi-biomarker approach in most aggre...

 exact-sciences-launches-initiative-with-mayo-clinic-to-provide-comprehensive-genomic-profiling-and-hereditary-cancer-tests-to-patients

The initiative expands the collection of data accessible to Mayo Clinic researchers and clinicians to advance cancer research a...

 citigroup-maintains-buy-on-exact-sciences-announces-100-price-target

Citigroup analyst Patrick Donnelly maintains Exact Sciences (NASDAQ:EXAS) with a Buy and announces $100 price target.

 championx-montrose-environmental-group-and-other-big-stocks-moving-higher-on-tuesday

U.S. stocks were lower, with the Dow Jones falling around 400 points on Tuesday.

 rex-american-resources-reports-upbeat-earnings-joins-avalo-therapeutics-rh-and-other-big-stocks-moving-higher-on-thursday

U.S. stocks were slightly higher, with the S&P 500 gaining around 0.1% on Thursday. Shares of REX American Resources Corpo...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION